Skip to main content

Advertisement

SpringerLink
Log in

Preparation and Characterization of the Sulfobutylether-β-Cyclodextrin Inclusion Complex of Amiodarone Hydrochloride with Enhanced Oral Bioavailability in Fasted State

  • Review Article
  • Published:
AAPS PharmSciTech Aims and scope Submit manuscript

Abstract

Amiodarone hydrochloride (AMD) is used in the treatment of a wide range of cardiac tachyarrhythmias, including both ventricular fibrillation (VF) and hemodynamically unstable ventricular tachycardia (VT). The objectives of this study were to improve the solubility and bioavailability in fasted state and to reduce the food effect of AMD by producing its inclusion complex with sulfobutylether-β-cyclodextrin (SBE-β-CD). The complex was prepared through a saturated water solution combined with the freeze-drying method and then characterized by Fourier transform infrared spectroscopy, proton nuclear magnetic resonance spectroscopy, and differential scanning calorimetry. The solubilities of AMD and its complex were 0.35 and 68.62 mg/mL, respectively, and the value of the inclusion complex was significantly improved by 196-fold compared with the solubility of free AMD. The dissolution of the AMD-SBE-β-CD inclusion complex in four different dissolution media was larger than that of the commercial product. The cumulative dissolution was more than 85% in water, pH 4.5 NaAc-HAC buffer, and pH 1.2 HCl aqueous solution. Moreover, the pharmacokinetic study found that the C max, AUC(0–t), and AUC(0–∞) of the AMI-SBE-β-CD inclusion complex had no significant difference in fasted and fed state, which indicated that the absorption of the AMI-SBE-β-CD inclusion complex in fasted state was increased and not affected by food.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9

Similar content being viewed by others

References

  1. Gholam D, Fizazi K, Terrier-Lacombe MJ, et al. Advanced seminoma—treatment results and prognostic factors for survival after first-line, cisplatin-based chemotherapy and for patients with recurrent disease. Cancer. 2003;98:745–52.

    Article  PubMed  Google Scholar 

  2. Brembilla-Perrot B. Risk of increasing incidence of atrial flutter, the most frequent arrhythmia, after repaired congenital heart disease. Int J Cardiol. 2000;75:138–9.

    Article  CAS  PubMed  Google Scholar 

  3. Hulst AVD, Roest A. Relation of prolonged tissue Doppler imaging-derived atrial conduction time to atrial arrhythmia in adult patients with congenital heart disease. Am J Cardio. 2012;109:1792–6.

    Article  Google Scholar 

  4. Otsuru T, Iijima S, Tsujimura N, et al. A case of small intestinal cancer repeating an ileus symptom complicated with refractory arrhythmia. Gan To Kagaku Ryoho. 2015;42:120–7.

    Google Scholar 

  5. Zhou H, Xu M, Gao Y, et al. Matrine induces caspase-independent program cell death in hepatocellular carcinoma through bid-mediated nuclear translocation of apoptosis inducing factor. Mol Cancer. 2014;13:1–11.

    Article  Google Scholar 

  6. Winkle RA, Glantz SA, Harrison DC. Pharmacologic therapy of ventricular arrhythmias. Am J Cardiol. 1975;36:629–50.

    Article  CAS  PubMed  Google Scholar 

  7. Ward DE, Camm AJ, Spurrell RA. Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. Heart. 1980;44:91–5.

    Article  CAS  Google Scholar 

  8. Williams EMV. Relevance of cellular to clinical electrophysiology in interpreting antiarrhythmic drug action. Am J Cardiol. 1989;64:5–9.

    Article  Google Scholar 

  9. Telichowski A, Banasiak W, Bobak J, et al. The effect of long term use of amiodarone hydrochloride on time and frequency domain parameters of signal averaged electrocardiogram in patients with ischemia heart disease. Pol Merkur Lekarski. 1997;2:378–81.

    CAS  PubMed  Google Scholar 

  10. Frangin G, Munoz A. Use of antiarrhythmic compounds in the prevention of post-infarction mortality. Patent No. US 5985915.

  11. Cui G, Sager PT, Singh BN, et al. Different effects of amiodarone and quinidine on the homogeneity of myocardial refractoriness in patients with intraventricular conduction delay. J Cardiovasc Pharmacol. 1998;3:201–8.

    Article  CAS  Google Scholar 

  12. Herendael HV, Dorian P. Amiodarone for the treatment and prevention of ventricular fibrillation and ventricular tachycardia. Vasc Health Risk Manag. 2010;6:465–72.

    PubMed  PubMed Central  Google Scholar 

  13. Pfisterer ME, Kiowski W, Brunner H, et al. Long-term benefit of 1-year amiodarone treatment for persistent complex ventricular arrhythmias after myocardial infarction. Circulation. 1993;87:309–11.

    Article  CAS  PubMed  Google Scholar 

  14. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med. 1996;333:77–82.

    Article  Google Scholar 

  15. Ravin LJ, Shami EG, Rattie ES. Micelle formation and its relationship to solubility behavior of 2-butyl-3-benzofuranyl-4-(2-(diethylamino)ethoxy)-3,5-diiodophenyl ketone hydrochloride. J Pharm Sci. 1975;64:1830–3.

    Article  CAS  PubMed  Google Scholar 

  16. Rubim AM, Rubenick JB, Gregolin E, et al. Amiodarone hydrochloride: enhancement of solubility and dissolution rate by solid dispersion technique. Braz J Pharm Sci. 2015;51:957–66.

    Article  Google Scholar 

  17. Kakavand B, Di ST. Unusual amiodarone toxicity in a child. JPPT. 2008;13:93–5.

    PubMed  PubMed Central  Google Scholar 

  18. Courchesne WE. Amiodarone as an antifungal agent. Patent No. 6221903.

  19. Atanasova I, Terziivanov PD. Evaluation of average bioequivalence of two oral formulations of amiodarone hydrochloride after single administration to healthy volunteers. Clin Drug Investig. 2001;21:423–8.

    Article  CAS  Google Scholar 

  20. Barle EL, Černe M, Peternel L, et al. Reduced intravenous toxicity of amiodarone nanosuspension in mice and rats. Drug Chem Toxicol. 2013;36:263–9.

    Article  CAS  PubMed  Google Scholar 

  21. Elgart A, Cherniakov I, Aldouby Y, et al. Improved oral bioavailability of BCS class 2 compounds by self nano-emulsifying drug delivery systems (SNEDDS): the underlying mechanisms for amiodarone and talinolol. Pharm Res. 2013;30:3029–44.

    Article  CAS  PubMed  Google Scholar 

  22. Riekes MK, Tagliari MP, Granada A, et al. Enhanced solubility and dissolution rate of amiodarone by complexation with β-cyclodextrin through different methods. Mater Sci Eng. 2010;30:1008–13.

    Article  CAS  Google Scholar 

  23. Xie Y, Ping X, Xin S, et al. Preparation of esomeprazole zinc solid dispersion and study on its pharmacokinetics. Int J Pharm. 2008;360:53–7.

    Article  CAS  PubMed  Google Scholar 

  24. Rywik, Stefan L, et al. Heart failure in patients seeking medical help at outpatients clinics. Part I. General characteristics. Eur J Heart Fail. 2000;2:413–21.

    Article  CAS  PubMed  Google Scholar 

  25. Renke M, Pl MG, Zegrzda D, et al. Interrelationship between cardiac structure and function and incidence of arrhythmia in peritoneal dialysis patients. Int J Artif Organs. 2001;24:374–9.

    CAS  PubMed  Google Scholar 

  26. Anvari A, Janisiw M, Türel Z, et al. Platelet glycoprotein Ia gene dimorphism α2-807 in malignant arrhythmia in coronary artery disease. Thromb Res. 2000;98:281–6.

    Article  CAS  PubMed  Google Scholar 

  27. Sideris DA, Toumanidis ST, Kostis EB, et al. Arrhythmogenic effect of high blood pressure: some observations on its mechanism. Cardiovasc Res. 1989;23:983–92.

    Article  CAS  PubMed  Google Scholar 

  28. Tükek T, Yildiz P, Atilgan D, et al. Effect of diurnal variability of heart rate on development of arrhythmia in patients with chronic obstructive pulmonary disease. Int J Cardiol. 2003;88:199–206.

    Article  PubMed  Google Scholar 

  29. Meng X, Mojaverian P, Doedée M, et al. Bioavailability of amiodarone, tablets administered with and without food in healthy subjects. Am J Cardiol. 2001;87:432–5.

    Article  CAS  PubMed  Google Scholar 

  30. Saida S, Achour S, Malika B, et al. Host–guest interaction between 3,4-dihydroisoquinoline-2(1H)-sulfonamide and β-cyclodextrin: spectroscopic and molecular modeling studies. J Mol Struct. 2013;1052:8–16.

    Article  Google Scholar 

  31. Omari MMA, Zughul MB, Davies JED, et al. Thermodynamic enthalpy–entropy compensation effects observed in the complexation of basic drug substrates with β-cyclodextrin. J Inclusion Phenom Macrocyclic Chem. 2007;57:379–84.

    Article  Google Scholar 

  32. Jarho P, Urtti A, Järvinen T. Hydroxypropyl-β-cyclodextrin increases the aqueous solubility and stability of pilocarpine prodrugs. Pharm Res. 1995;12:1371–5.

    Article  CAS  PubMed  Google Scholar 

  33. Davis ME, Brewster ME. Cyclodextrin-based pharmaceutics: past, present and future. Nat Rev Drug Discov. 2005;3:1023–35.

    Article  Google Scholar 

  34. Nicolazzi C, Venard V, Faou AL, et al. In vitro antiviral efficacy of the ganciclovir complexed with beta-cyclodextrin on human cytomegalovirus clinical strains. Antiviral Res. 2002;54:121–7.

    Article  CAS  PubMed  Google Scholar 

  35. Raghavan, Krishnaswamy S, Malloy, Timothy M, Varia, Sailesh A. Complex of ras-farnesyltransferase inhibitor and sulfobutylether-7-β-cyclodextrin or 2-hydroxypropyl-β-cyclodextrin and method. Patent No. US6218375.

  36. Popescu C, Lu W, Zhou L, et al. Lorazepam complexation with hydroxypropyl-β-cyclodextrin (HP-β-CD) and sulfobutylether-β-cyclodextrin (SBE-β-CD): phase solubility parameters evaluation. Aaps Meeting. 2012.

  37. Shen N, Minxia N, Hairu N, et al. Study on the inclusion behavior of sulfobutylether-beta-cyclodextrin with perphenazine by flow injection chemiluminescence. B Korean Chem. 2013;34:3199–205.

    Article  CAS  Google Scholar 

  38. Higuchi T, Connors KA. Phase solubility techniques. Adv Anal Chem Instrum. 1965;4:117–212.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Pharmacy, Nanjing Tech University, 5th Mofan Road, Nanjing, 21009, China

    Dandan Wang, Guoguang Chen & Lili Ren

Authors
  1. Dandan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Guoguang Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lili Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Guoguang Chen.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, D., Chen, G. & Ren, L. Preparation and Characterization of the Sulfobutylether-β-Cyclodextrin Inclusion Complex of Amiodarone Hydrochloride with Enhanced Oral Bioavailability in Fasted State. AAPS PharmSciTech 18, 1526–1535 (2017). https://doi.org/10.1208/s12249-016-0646-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1208/s12249-016-0646-4

KEY WORDS

Search

Navigation